Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-24-003924
Filing Date
2024-11-14
Accepted
2024-11-14 19:21:58
Documents
2
Group Members
JEFF EASTONLIND GLOBAL PARTNERS II LLC

Document Format Files

Seq Description Document Type Size
1 sch13g.htm SC 13G/A 66757
2 exhibit99-1.htm EX-99.1 7430
  Complete submission text file 0000929638-24-003924.txt   75976
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Subject) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-80136 | Film No.: 241465193
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund II LP (Filed by) CIK: 0001871665 (see all company filings)

EIN.: 863914253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A